Iradimed (IRMD) EBIT (2013 - 2026)

Iradimed (IRMD) has 14 years of EBIT data on file, last reported at $7.2 million in Q1 2026.

• On a quarterly basis, EBIT rose 33.23% year-over-year to $7.2 million in Q1 2026; TTM through Mar 2026 was $28.0 million, a 23.42% increase from a year earlier, with the FY2025 full-year figure at $26.1 million, up 19.04% from the prior year.
• EBIT for Q1 2026 stood at $7.2 million, up from $7.1 million in the prior quarter.
• Over the last five years, EBIT for IRMD reached as high as $7.2 million in Q1 2026 and fell as low as $3.1 million in Q1 2022.
• Historically, EBIT has averaged $5.4 million across 5 years, with a median of $5.4 million in 2025.
• Across the five-year window, EBIT surged 125.93% in 2022 and retreated 1.97% in 2024, its largest moves.
• Year by year, EBIT stood at $4.3 million in 2022, then grew by 21.3% to $5.2 million in 2023, then advanced by 12.42% to $5.8 million in 2024, then advanced by 22.3% to $7.1 million in 2025, then advanced by 2.02% to $7.2 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $7.2 million in Q1 2026, $7.1 million in Q4 2025, and $6.8 million in Q3 2025.